Klein Virag, Michely Anna, Hempel Paulina, Katona Istvan, Tenbrock Klaus, Martin Christian, Verjans Eva
Department of Pediatrics, Medical Faculty, RWTH Aachen, University Hospital Aachen, Aachen, Germany.
Institute of Pharmacology and Toxicology, Medical Faculty, RWTH Aachen, University Hospital Aachen, Aachen, Germany.
Sci Rep. 2025 Sep 12;15(1):32436. doi: 10.1038/s41598-025-16935-0.
Bronchial asthma is a chronic inflammatory disease with rising prevalence worldwide. Apart from the immunological role of the tricyclic antidepressant amitriptyline in bronchial asthma, there is emerging evidence that inhaled amitriptyline directly reduces acute bronchoconstriction. However, the mechanism by which amitriptyline influences bronchial tone remains poorly understood. To influence bronchoconstriction, rat precision-cut lung slices treated with varying concentrations of amitriptyline (0-5 µM) and incubated with inhibitors targeting different signaling pathways. Amitriptyline reduces acetylcholine- and serotonin-induced bronchoconstriction. Neither the muscarinic antagonist ipratropium nor the phospholipase C inhibitor U73122, nor the protein kinase C inhibitor chelerythrine diminished the effect of amitriptyline. Inhibition of calcium sensitizing and induction failed to alter amitriptyline's effect on bronchoconstriction. Caveolae-as part of the plasma membrane-display a microenvironment, where regulation of signal transduction takes place. Similar to methyl ß cyclodextrin (MBCD), a common substance to destroy caveolae, amitriptyline dramatically reduced the number of caveolae in lung tissue. However, unlike MBCD, this effect could not be explained by cholesterol depletion alone, as cholesterol repletion did not reverse amitriptyline's effect. Furthermore, neither simvastatin (a lipid lowering agent) nor cytochalasin D (an inhibitor of actin polymerization), influenced the inhibitory effect of amitriptyline on bronchoconstriction. In conclusion, amitriptyline inhibits bronchoconstriction independently of direct receptor binding or interaction. It also reduces the total number of caveolae without effects on cholesterol lowering pathways or actin depolymerization. A more general mechanism seems likely, as inhibition of single signal transduction pathways failed. Further studies are required to elucidate the underlying mechanisms.
支气管哮喘是一种慢性炎症性疾病,在全球范围内患病率呈上升趋势。除了三环类抗抑郁药阿米替林在支气管哮喘中的免疫作用外,越来越多的证据表明吸入阿米替林可直接减轻急性支气管收缩。然而,阿米替林影响支气管张力的机制仍知之甚少。为了研究对支气管收缩的影响,用不同浓度的阿米替林(0-5μM)处理大鼠精密肺切片,并与靶向不同信号通路的抑制剂一起孵育。阿米替林可减轻乙酰胆碱和5-羟色胺诱导的支气管收缩。毒蕈碱拮抗剂异丙托溴铵、磷脂酶C抑制剂U73122或蛋白激酶C抑制剂白屈菜红碱均未减弱阿米替林的作用。抑制钙敏化和诱导未能改变阿米替林对支气管收缩的作用。小窝作为质膜的一部分,呈现出一个发生信号转导调节的微环境。与破坏小窝的常见物质甲基-β-环糊精(MBCD)类似,阿米替林显著减少了肺组织中小窝的数量。然而,与MBCD不同的是,这种作用不能仅用胆固醇耗竭来解释,因为补充胆固醇并不能逆转阿米替林的作用。此外,辛伐他汀(一种降脂药物)和细胞松弛素D(肌动蛋白聚合抑制剂)均未影响阿米替林对支气管收缩的抑制作用。总之,阿米替林独立于直接受体结合或相互作用抑制支气管收缩。它还减少了小窝的总数,而对胆固醇降低途径或肌动蛋白解聚没有影响。由于单一信号转导途径的抑制失败,似乎存在更普遍的机制。需要进一步研究以阐明其潜在机制。